CRIO Innovation Theater: Creating an EMR to EDC pipeline through eSource

The CRIO Innovation Theater: Creating an EMR to EDC pipeline through eSource, presented insights to a jam-packed audience at DIA’s 2022 Global Annual Meeting. In case you missed it, view the recording right here, courtesy of DIA.

Overview

EMR-to-EDC integration is challenging to scale due to the fragmentation of health care providers. With EMR interoperability, patients have the power to collect their own medical records and direct them into e-clinical platforms. CRIO and Pluto Health will demonstrate a groundbreaking innovation whereby Pluto Health aggregates medical records on behalf of patients and sends them to CRIO’s integrated eSource-to-EDC platform, thus creating the industry’s first truly scalable EMR-to-EDC pipeline.

Panelists:

Dr. Elena Christofides, CEO at Endocrinology Associates Inc.

Raymond Nomizu, CEO and co-founder at CRIO

Dr. Seung Park, Head of Medical Informatics at Pluto Health

SCHEDULE A DEMO to discover more.

Progress Notes are Vital to Source Data

Progress notes are free-text entries by the investigator, coordinator or study team member that are inserted into the source record. Generally, these play a critical and highly undervalued role in the study process. Progress notes are often used to: Clarify or confirm any data points that may appear as outliers, even before a query is...

Sponsors, Funding is Tight – Be Smart with Your Money

Getting a new product to market is expensive. There are a variety of studies and research that point to a wide array of costs, but generally speaking, it costs nearly $3 billion dollars to bring a new drug to market. Yes, you read that correctly. Beyond this, the success rate of a new compound to...

The FDA’s Decentralized Clinical Trials Draft Guidance Explained

The highly anticipated Decentralized Clinical Trials (DCT) draft guidance from the FDA was finally released on 02-May-2023. In this 19-page document, the FDA outlines its current thinking around the concept of DCTs. From the outset of the draft guidance, the FDA makes a clear point on what DCTs can mean for patients and the patient...